United States: USPTO Reveals Strategic Plan for 2022–2026
The United States Patent and Trademark Office (USPTO) published its 2022-2026 Strategic Plan on June 7, 2023, finishing a planning process that included more than 150 comments from the public and USPTO staff members on the draft version.
The updated strategy defines the USPTO’s mission-driven strategic objectives:
- Drive inclusive U.S. innovation and global competitiveness;
- Promote the efficient delivery of reliable intellectual property (IP) rights;
- Promote the protection of IP against new and persistent threats;
- Bring innovation to impact the public good; and
- Generate impactful employee and customer experiences by maximizing agency operations.
With various objectives closely tied to each of these five aims, the plan directly supports the USPTO’s new purpose of advancing US innovation, inclusive capitalism, and global competitiveness, as well as its new vision of unleashing America’s potential.
The USPTO is continuing its efforts to minimize patent application pendency (now roughly 25 months to final disposition) by “reimagining patent examination processes” and giving alternative patent application processing choices. Based on this initiative, the USPTO may continue to extend its options for expedited examination of specific technologies and/or increase the number of annual Track I requests granted. Practitioners should continue to use the present programs to accelerate prosecution at the USPTO and explore more methods to expedite prosecution.
Applicants can expect amendments to USPTO search procedures. Although it’s uncertain how these improvements will play out in practice, they could make it possible to identify the most significant prior art with more accuracy.
First, the USPTO wants to maximize the strategic integration of artificial intelligence (AI) and robotic process automation (RPA) into the patent application system, including for improved and more effective prior art access.
Second, the USPTO intends to give examiners additional instruction and resources so they may explore databases kept by the FDA. This expands on the ground-breaking cooperation between the FDA and USPTO in 2022. To fulfill their need to disclose, companies must guarantee consistency in their patent and regulatory plans and submit to the USPTO any correspondence with the FDA that is pertinent.
***Other Articles***
– You could check the Required documents for filing a trademark in the USA here.
– You could see What needs to be done after registering a trademark in the US? here.
– You could visit here to see What is used in commerce of filing trademarks in the USA.
– You could also check here to see the Procedure for the Trademark in the USA.
Contact AAA IPRIGHT: Email: [email protected]
Or sending your inquiry by filling the form:
